Cargando…

Gene Expression Indicates Altered Immune Modulation and Signaling Pathway Activation in Ovarian Cancer Patients Resistant to Topotecan

Epithelial ovarian cancer (EOC) is one of the deadliest gynecological malignancies. Topotecan remains an essential tool in second-line therapy; even so, most patients develop resistance within a short period of time. We aimed to identify biomarkers of topotecan resistance by using gene expression si...

Descripción completa

Detalles Bibliográficos
Autores principales:	Menyhárt, Otília, Fekete, János Tibor, Győrffy, Balázs
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6600443/ https://www.ncbi.nlm.nih.gov/pubmed/31195594 http://dx.doi.org/10.3390/ijms20112750

Ejemplares similares

Gene expression-based biomarkers designating glioblastomas resistant to multiple treatment strategies
por: Menyhárt, Otília, et al.
Publicado: (2021)

Demographic shift disproportionately increases cancer burden in an aging nation: current and expected incidence and mortality in Hungary up to 2030
por: Menyhárt, Otília, et al.
Publicado: (2018)

New Transcriptomic Biomarkers of 5-Fluorouracil Resistance
por: Fekete, János Tibor, et al.
Publicado: (2023)

Principles of tumorigenesis and emerging molecular drivers of SHH‐activated medulloblastomas
por: Menyhárt, Otília, et al.
Publicado: (2019)

Molecular stratifications, biomarker candidates and new therapeutic options in current medulloblastoma treatment approaches
por: Menyhárt, Otília, et al.
Publicado: (2020)

Multi-omics approaches in cancer research with applications in tumor subtyping, prognosis, and diagnosis
por: Menyhárt, Otília, et al.
Publicado: (2021)

A unified platform enabling biomarker ranking and validation for 1562 drugs using transcriptomic data of 1250 cancer cell lines
por: Tibor Fekete, János, et al.
Publicado: (2022)

Molecular markers and potential therapeutic targets in non-WNT/non-SHH (group 3 and group 4) medulloblastomas
por: Menyhárt, Otília, et al.
Publicado: (2019)

Determining consistent prognostic biomarkers of overall survival and vascular invasion in hepatocellular carcinoma
por: Menyhárt, Otília, et al.
Publicado: (2018)

MultipleTesting.com: A tool for life science researchers for multiple hypothesis testing correction
por: Menyhart, Otília, et al.
Publicado: (2021)

Correction: MultipleTesting.com: A tool for life science researchers for multiple hypothesis testing correction
por: Menyhart, Otília, et al.
Publicado: (2022)

Mutations Defining Patient Cohorts With Elevated PD-L1 Expression in Gastric Cancer
por: Menyhárt, Otília, et al.
Publicado: (2019)

miRNA Expression Signatures of Therapy Response in Squamous Cell Carcinomas
por: Fekete, János Tibor, et al.
Publicado: (2020)

Author Correction: Validation of miRNA prognostic power in hepatocellular carcinoma using expression data of independent datasets
por: Nagy, Ádám, et al.
Publicado: (2018)

Validation of miRNA prognostic power in hepatocellular carcinoma using expression data of independent datasets
por: Nagy, Ádám, et al.
Publicado: (2018)

The prognostic association of SPAG5 gene expression in breast cancer patients with systematic therapy
por: Zhu, Chenjing, et al.
Publicado: (2019)

Predictive biomarkers of immunotherapy response with pharmacological applications in solid tumors
por: Kovács, Szonja Anna, et al.
Publicado: (2023)

Metronomic Chemotherapy Based on Topotecan or Topotecan and Cyclophosphamide Combination (CyTo) in Advanced, Pretreated Ovarian Cancer
por: Wysocki, Piotr J., et al.
Publicado: (2023)

DUSP4 is associated with increased resistance against anti-HER2 therapy in breast cancer
por: Menyhart, Otília, et al.
Publicado: (2017)

Myotilin, a New Topotecan Resistant Protein in Ovarian Cancer Cell Lines
por: Sterzyńska, Karolina, et al.
Publicado: (2018)

Uncovering Potential Therapeutic Targets in Colorectal Cancer by Deciphering Mutational Status and Expression of Druggable Oncogenes
por: Menyhart, Otília, et al.
Publicado: (2019)

Co-Transmission of Alpha-Synuclein and TPPP/p25 Inhibits Their Proteolytic Degradation in Human Cell Models
por: Lehotzky, Attila, et al.
Publicado: (2021)

The Role of Matrix Gla Protein (MGP) Expression in Paclitaxel and Topotecan Resistant Ovarian Cancer Cell Lines
por: Sterzyńska, Karolina, et al.
Publicado: (2018)

Topotecan given as a 21-day infusion in the treatment of advanced ovarian cancer
por: Gore, M, et al.
Publicado: (2001)

Reduced cellular accumulation of topotecan: a novel mechanism of resistance in a human ovarian cancer cell line.
por: Ma, J., et al.
Publicado: (1998)

Commentary: Periocular topotecan for retinoblastoma
por: Sharma, Minal, et al.
Publicado: (2018)

Pharmacokinetically guided phase I trial of topotecan and etoposide phosphate in recurrent ovarian cancer
por: Levitt, N C, et al.
Publicado: (2005)

Successful local regional therapy with topotecan of intraperitoneally growing human ovarian carcinoma xenografts.
por: Pratesi, G., et al.
Publicado: (1995)

Phase II randomized study of PM01183 versus topotecan in patients with platinum-resistant/refractory advanced ovarian cancer
por: Poveda, A., et al.
Publicado: (2017)

MEK1 is associated with carboplatin resistance and is a prognostic biomarker in epithelial ovarian cancer
por: Pénzváltó, Zsófia, et al.
Publicado: (2014)

The Profile of MicroRNA Expression and Potential Role in the Regulation of Drug-Resistant Genes in Doxorubicin and Topotecan Resistant Ovarian Cancer Cell Lines
por: Stasiak, Piotr, et al.
Publicado: (2022)

Topotecan and Cyclophosphamide in Adults with Relapsed Sarcoma
por: Blanchette, P., et al.
Publicado: (2012)

Periocular topotecan for vitreous seeds in retinoblastoma
por: Sthapit, Purnima R, et al.
Publicado: (2018)

Discovery and ranking of the most robust prognostic biomarkers in serous ovarian cancer
por: Győrffy, Balázs
Publicado: (2023)

Dose and schedule-finding study of oral topotecan and weekly cisplatin in patients with recurrent ovarian cancer
por: Gelderblom, H, et al.
Publicado: (2001)

Topotecan synergizes with CHEK1 (CHK1) inhibitor to induce apoptosis in ovarian cancer cells
por: Kim, Marianne K, et al.
Publicado: (2015)

Heparin and Liver Heparan Sulfate Can Rescue Hepatoma Cells from Topotecan Action
por: Dudás, József, et al.
Publicado: (2014)

Optimization of liposomal topotecan for use in treating neuroblastoma
por: Chernov, Lina, et al.
Publicado: (2017)

Mini-Factor H Modulates Complement-Dependent IL-6 and IL-10 Release in an Immune Cell Culture (PBMC) Model: Potential Benefits Against Cytokine Storm
por: Kozma, Gergely Tibor, et al.
Publicado: (2021)

Development and Validation of an HPLC Method for Analysis of Topotecan in Human Cerebrospinal Fluid and Its Application in Elimination Evaluation of Topotecan after Intraventricular Injection
por: Yoshikawa, Naoki, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ckrr058novvacrlvgjtbuu2945